First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    Moderna, Inc.

    MRNA · 41 developments mapped · last assessed 2026-09-29

    Market Ontology has mapped 41 macro, policy, and market developments to Moderna, Inc. since 2026-08-12. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for MRNA yet, so no modelled value is shown. The MRNA valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run MRNA on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for MRNA. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy

      Direct commercialization opportunity for a novel oncology therapy, expanding addressable market beyond infectious diseases.

      · Moves peak sales estimates for oncology pipeline, probability of success for mrna oncology platform, discount rate reflecting reduced clinical risk

    • Open question

      Pfizer and Nvidia Back $80M AI Computational Immunology Venture

      Increased competitive pressure in vaccine development and AI-driven drug discovery from established players leveraging advanced computational methods.

      · Moves competitive landscape, r&d efficiency relative to peers

    What changed, by assumption

    Peak sales estimates for oncology pipeline
    • 2026-09-16Moderna and Merck Report Positive Phase III Trial Results for mRNA Cancer Therapy
    Probability of success pipeline
    • 2026-09-17Over 40 Late-Stage Hypertension Trials Progress Across RNAi and Novel Pathways
    R&d efficiency
    • 2026-09-25Pfizer and NVIDIA Form $80M CytoReason Venture as Vaccine AI R&D Expands
    • 2026-09-27Hangzhou Global Open-Source AI Challenge Awards 1M RMB to Peptide Algorithm
    • 2026-09-27Hangzhou Global Open-Source AI Finals Conclude with 1M RMB Biotech Prize
    • 2026-09-25Pfizer and NVIDIA Form $80M Joint Venture in AI-Driven Vaccine Discovery
    Competitive landscape
    • 2026-09-25Pfizer and Nvidia Back $80M AI Computational Immunology Venture
    • 2026-09-25Pfizer and NVIDIA Back $80M CytoReason Venture for AI Vaccine Adjuvant Discovery
    R&d intensity relative to peers
    • 2026-09-25Pfizer and Nvidia deploy $80M joint investment into CytoReason AI platform

    Assumption changes

    Full ledger →
    DateAssumptionDirectionWhyConf.
    2026-08-29Share countBullishIssuance of convertible senior notes typically leads to potential share count dilution upon conversion.0.90
    2026-08-29Interest expenseBullishCoupon adds to interest expense until conversion.0.70
    2026-08-29DilutionBullishConvertible issuance creates contingent dilution at conversion price.0.70
    2026-07-31Capital expenditureBearishCompany guidance for 2026 capital expenditures is $0.2 to $0.3 billion.0.90

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-29Oncolytics Biotech Inc Announces Publication of Pelareorep Liver Cancer Datawatch3-12m0.10
    2026-09-29Invivyd Announces Regulatory Submission Plans for VYD2311 via Accelerated Approval Programwatch3-12m0.20
    2026-09-29Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Millionwatch3-12m0.30
    2026-09-29Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Priority Review Voucherwatch3-12m0.30
    2026-09-27Hangzhou Global Open-Source AI Challenge Awards 1M RMB to Peptide AlgorithmBullish3-12m0.30
    2026-09-27Hangzhou Global Open-Source AI Finals Conclude with 1M RMB Biotech PrizeBullish1-5y0.30
    2026-09-25Moleculin Biotech, Inc. Announces New Preclinical Data for Annamycin in Pancreatic Cancer at AACRwatch3-12m0.20
    2026-09-25Pfizer and NVIDIA Form $80M Joint Venture in AI Biopharma Platform CytoReasonmixed3-12m0.30
    2026-09-25Pfizer and Nvidia Back $80M AI Computational Immunology Venturewatch1-3m0.40
    2026-09-25Pfizer and Nvidia deploy $80M joint investment into CytoReason AI platformmixed1-5y0.40
    2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqBullish1-3m0.20
    2026-09-25Pfizer and Nvidia Form $80M CytoReason AI Drug Discovery JVwatch3-12m0.40